Abd El-Khalik Sarah Ragab, Nasif Elham, Arakeep Heba M, Rabah Hanem
Medical Biochemistry Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Medical Physiology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Biol Trace Elem Res. 2022 Apr;200(4):1677-1687. doi: 10.1007/s12011-021-02773-4. Epub 2021 Jul 9.
Diabetic nephropathy (DN) as one of the common microvascular complications of diabetes mellitus, is the main cause of end-stage renal disease. Zinc oxide nanoparticles (ZnO NPs) have been employed in several biomedical aspects. This study purposed to explore the mechanistic renoprotective effects of ZnO NPs in STZ-induced DN. Sixty male Wistar rats were allocated into four equal groups: control, ZnO NPs control, STZ, and STZ + ZnO NPs groups. At the end of the experiment, blood and urine biochemical parameters were assayed. Renal tissue level of advanced glycation end products (AGEs) was assayed spectrofluorometrically, moreover, nuclear factor erythroid 2-related factor 2 (Nrf2) DNA-binding activity and IL-1β levels were detected by ELISA. The gene expression levels of thioredoxin-interacting protein (TXNIP) and NOD-like receptor family pyrin domain containing 3 (NLRP3) were detected by quantitative real-time PCR. Oxidative stress markers were determined spectrophotometrically. Also, renal tissue histopathological and immunohistochemical analyses were determined. After 6 weeks of treatment, ZnO NPs markedly improved the biochemical, renal functions, and histopathological findings. Furthermore, ZnO NPs significantly increased Nrf2-DNA-binding activity and downregulated TXNIP gene expression leading to restoration of the redox status. Additionally, ZnO NPs ameliorated AGEs levels, enhanced autophagy activity, and attenuated inflammasome activation via downregulation of NLRP3 expression and reducing IL-1β levels. Based on our results, we concluded that ZnO NPs can be considered as a promising agent for slowing the progression of DN via interplay between autophagy and Nrf2/TXNIP/NLRP3 inflammasome signaling.
糖尿病肾病(DN)作为糖尿病常见的微血管并发症之一,是终末期肾病的主要原因。氧化锌纳米颗粒(ZnO NPs)已被应用于多个生物医学领域。本研究旨在探讨ZnO NPs对链脲佐菌素诱导的DN的肾脏保护作用机制。将60只雄性Wistar大鼠分为四组,每组15只:对照组、ZnO NPs对照组、链脲佐菌素组和链脲佐菌素+ZnO NPs组。实验结束时,检测血液和尿液生化指标。采用荧光分光光度法检测肾组织晚期糖基化终产物(AGEs)水平,此外,通过ELISA检测核因子红细胞2相关因子2(Nrf2)的DNA结合活性和IL-1β水平。采用定量实时PCR检测硫氧还蛋白相互作用蛋白(TXNIP)和含NOD样受体家族吡咯结构域3(NLRP3)的基因表达水平。用分光光度法测定氧化应激标志物。同时,进行肾组织病理和免疫组化分析。治疗6周后,ZnO NPs显著改善了生化指标、肾功能和组织病理学结果。此外,ZnO NPs显著增加Nrf2-DNA结合活性,下调TXNIP基因表达,从而恢复氧化还原状态。此外,ZnO NPs降低了AGEs水平,增强了自噬活性,并通过下调NLRP3表达和降低IL-1β水平减轻了炎性小体激活。基于我们的研究结果,我们得出结论,ZnO NPs可被认为是一种有前途的药物,通过自噬与Nrf2/TXNIP/NLRP3炎性小体信号之间的相互作用来减缓DN的进展。